Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors in the central nervous system, conolidine modulates alternate molecular targets. A Science Advancements review found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By influencing https://alfredn246kco0.blogs100.com/profile